Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)

Background. Increasing antimicrobial resistance among pathogens causing complicated intra-abdominal infections (cIAIs) supports the development of new antimicrobials. Ceftolozane/tazobactam, a novel antimicrobial therapy, is active against multidrug-resistant Pseudomonas aeruginosa and most extended...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomkin, Joseph, Hershberger, Ellie, Miller, Benjamin, Popejoy, Myra, Friedland, Ian, Steenbergen, Judith, Yoon, Minjung, Collins, Sylva, Yuan, Guojun, Barie, Philip S., Eckmann, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
Articles and Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412191/
https://www.ncbi.nlm.nih.gov/pubmed/25670823
http://dx.doi.org/10.1093/cid/civ097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4412191/
https://www.ncbi.nlm.nih.gov/pubmed/25670823
http://dx.doi.org/10.1093/cid/civ097

Ejemplares similares